Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.
An increasing number of PhD students are concerned about their career prospects. Currently, only around 5-10% of PhD graduates remain in academia — the vast majority have to navigate an unfamiliar job market, where industry demand for their highly educated profiles appears to be in decline. Is a PhD still the best route to professional success? And what can students do to prepare themselves?
In Antwerp, a unique cohort of volunteers is helping to solve one of the world's most urgent medical challenges: the early detection of cognitive decline. While the study is local, its implications are global — providing the long-term data needed to understand the hidden years of decline in Alzheimer's disease and other forms of dementia, to enable early diagnosis and intervention.
Behind the vivid colors of our phone screens and smartwatches lies a world too small for the naked eye to see. But scientists at the University of Antwerp have developed a new method to analyze small changes in the atomic arrangement of the nanomaterials in these kinds of digital displays, which is key to creating stable and efficient materials for solar cells or electronics in the future.
Europe’s healthtech scene is buzzing, with innovators racing to re-shape how we prevent, diagnose and treat disease. Many of the field’s brightest stars will gather at the HealthTech Investor Summit in December to connect, compare notes and compete for attention. Ahead of the event, we asked one of the participating investors, Vlaamse Investeringsmaatschappij Vlaanderen (PMV) what they’re scouting for in Europe’s future healthtech champions.
Antibodies have long held promise as a ‘magic bullet’ for cancer therapies, yet many antibody-drug conjugates face issues with toxicity and resistance. Belgian startup ATB Therapeutics is producing a new type of weaponized antibodies, using plants as mini factories for safe, effective cancer and autoimmune treatments.
For the many women who develop metastatic breast cancer, treatment options are increasingly determined using blood-based diagnostics. But there are many other bodily fluids that can also be screened, potentially opening doors to new therapies for these patients. This broader approach to testing could improve clinical trial designs and be extended to other cancer types.
VIB’s podcast Called to Science is back for a second season—a series where science journalist Brad Van Paridon sits with researchers to go beyond the science: exploring the passion, setbacks, and big questions that motivate them. In this episode, Bart Lambrecht—director of the VIB Center for Inflammation Research and a practicing physician at Ghent University Hospital—dives into the overlaps between treating patients, running a lab, and the fascination that drives him forward.
Belgium puts a lot of resources into research and innovation, supporting the creation of spinouts and startups with brilliant potential health solutions. But as they grow, most of those companies eventually hit a point where local support isn’t enough—they have to look beyond Europe for their manufacturing, clinical trials, and funding needs. How can Belgium close this gap so companies can stay and thrive in Europe?
Belgium’s flagship “biology meets technology” conference returns to Brussels this fall with a clear message: collaboration is key to keeping Europe at the front of health innovation. On 4 November 2025, Science for Health will explore how Belgium’s regional strengths and synergies can be combined to accelerate ATMP and new modalities—such as radioligand therapies and digital health solutions—to reinforce the country's global position in biotech and healthtech.
Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.
An increasing number of PhD students are concerned about their career prospects. Currently, only around 5-10% of PhD graduates remain in academia — the vast majority have to navigate an unfamiliar job market, where industry demand for their highly educated profiles appears to be in decline. Is a PhD still the best route to professional success? And what can students do to prepare themselves?
In Antwerp, a unique cohort of volunteers is helping to solve one of the world's most urgent medical challenges: the early detection of cognitive decline. While the study is local, its implications are global — providing the long-term data needed to understand the hidden years of decline in Alzheimer's disease and other forms of dementia, to enable early diagnosis and intervention.
Behind the vivid colors of our phone screens and smartwatches lies a world too small for the naked eye to see. But scientists at the University of Antwerp have developed a new method to analyze small changes in the atomic arrangement of the nanomaterials in these kinds of digital displays, which is key to creating stable and efficient materials for solar cells or electronics in the future.
Europe’s healthtech scene is buzzing, with innovators racing to re-shape how we prevent, diagnose and treat disease. Many of the field’s brightest stars will gather at the HealthTech Investor Summit in December to connect, compare notes and compete for attention. Ahead of the event, we asked one of the participating investors, Vlaamse Investeringsmaatschappij Vlaanderen (PMV) what they’re scouting for in Europe’s future healthtech champions.
Antibodies have long held promise as a ‘magic bullet’ for cancer therapies, yet many antibody-drug conjugates face issues with toxicity and resistance. Belgian startup ATB Therapeutics is producing a new type of weaponized antibodies, using plants as mini factories for safe, effective cancer and autoimmune treatments.
For the many women who develop metastatic breast cancer, treatment options are increasingly determined using blood-based diagnostics. But there are many other bodily fluids that can also be screened, potentially opening doors to new therapies for these patients. This broader approach to testing could improve clinical trial designs and be extended to other cancer types.
VIB’s podcast Called to Science is back for a second season—a series where science journalist Brad Van Paridon sits with researchers to go beyond the science: exploring the passion, setbacks, and big questions that motivate them. In this episode, Bart Lambrecht—director of the VIB Center for Inflammation Research and a practicing physician at Ghent University Hospital—dives into the overlaps between treating patients, running a lab, and the fascination that drives him forward.
Belgium puts a lot of resources into research and innovation, supporting the creation of spinouts and startups with brilliant potential health solutions. But as they grow, most of those companies eventually hit a point where local support isn’t enough—they have to look beyond Europe for their manufacturing, clinical trials, and funding needs. How can Belgium close this gap so companies can stay and thrive in Europe?
Belgium’s flagship “biology meets technology” conference returns to Brussels this fall with a clear message: collaboration is key to keeping Europe at the front of health innovation. On 4 November 2025, Science for Health will explore how Belgium’s regional strengths and synergies can be combined to accelerate ATMP and new modalities—such as radioligand therapies and digital health solutions—to reinforce the country's global position in biotech and healthtech.